en · de · es · pt
cjc-1295-notes.peptides3081.com › Blog › Structure And Receptor Pharmacology — Hands-On Walkthrough

Structure And Receptor Pharmacology — Hands-On Walkthrough

By Editorial Desk · published 2026-05-25 · last reviewed 2026-07-17 · Blog

Lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Handling Storage And Analytical Methods

Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.

Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.

Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

Albumin Binding and Duration of Action

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Related pages on this site

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Receptor Action and Pharmacokinetics

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Background and Naming Conventions

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Notes from published material

Once the planula is securely on its substrate, a stalk grows out of the holdfast and, eventually, a hydranth, also known as a gastrozooid (an individual polyp specializing in feeding) forms on the anterior end of the stalk. At this stage, the planula is now considered a primary polyp, and this polyp can propagate vegetatively by extending its stolon to form a connected colony of multiple polyps. Once it begins to aseuxally reproduce, the colony rapidly increases in size and can frequently survive predation so long as a part of it remains uneaten. In addition to the feeding gastrozooids, a mature polyp colony has reproductive gonozooids that produce baby medusa by budding. These medusa reach maturity after 2–3 weeks.

The entrance to the Cothon at Carthage was protected by a chain. The chain at Fort Blockhouse, protecting Portsmouth Harbour from 1431 to 1539. The Leonine Wall included a chain blocking the Tiber A chain spanned the Golden Horn A chain and boom blocked the River Medway during the Raid on the Medway Hudson River Chain The chain blocking the Parana River during the Battle of Vuelta de Obligado A chain was placed from Columbus, Kentucky across the Mississippi River to Missouri in order to block Union ships during the American Civil War Between the A Palma Castle in Mugardos and Saint Philip Castle, in ria of Ferrol, to defend the city and naval base.

Trump and his administration's Make America Healthy Again agenda promoted various anti-science and anti-vaccine claims, which led to a resurgence of whooping cough and measles. They alleged they were working against Big Pharma. On November 14, Trump announced that he would nominate Robert F. Kennedy Jr. for Health and Human Services Secretary. This was controversial given Kennedy's repeated endorsement of anti-vaccine conspiracy theories. The director of the American Public Health Association, America's largest organization of public health professionals, said, "He is not competent by training, management skills, temperament or trust to have this job." On February 18, Trump signed an executive order calling for the policy recommendations for reducing the out-of-pocket costs of In Vitro Fertilisation. On February 25, Trump signed an executive order to improve healthcare cost transparency.

Philip Hampton, at that time chair of the Royal Bank of Scotland, became GSK chairman in September 2015. On 31 March 2017, Emma Walmsley became CEO. She is the first female CEO of the company. In December 2017, Reuters reported that Glaxo had increased its stake in its Saudi Arabian unit to 75% (from 49%) taking over control from its Saudi partner Banaja KSA Holding Company. With respect to rare diseases, the company divested its portfolio of gene therapy drugs to Orchard Therapeutics in April 2018. In November 2018, Reuters reported that Unilever was in prime position to acquire GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in a sale that could generate around US$4 billion for the company. Nestlé and Coca-Cola have also been reported to be interested in the business unit as they look to strengthen their presence in India. On 3 December 2018, GSK announced that Unilever would acquire the Indian-listed GlaxoSmithKline Consumer Healthcare business for US$3.8 billion (£2.98 billion). Unilever will pay the majority of the deal in cash, with the remaining being paid in shares in its Indian operation, Hindustan Unilever Limited. Upon completion, GSK will then own around 5.7% of Hindustan Unilever Limited, selling those shares in a number of tranches. The same day, the company also announced it would acquire oncology specialist, Tesaro, for US$5.1 billion. The deal will give GSK control of ovarian cancer treatment, Zejula - a member of the class of poly ADP ribose polymerase (PARP) inhibitors.

=== Robotic, mobile laboratory operators and remote-controlled laboratories === In July 2020 scientists reported the development of a mobile robot chemist and demonstrate that it can assist in experimental searches. According to the scientists their strategy was automating the researcher rather than the instruments – freeing up time for the human researchers to think creatively – and could identify photocatalyst mixtures for hydrogen production from water that were six times more active than initial formulations. The modular robot can operate laboratory instruments, work nearly around the clock, and autonomously make decisions on his next actions depending on experimental results. There is ongoing development of "remote controlled laboratories" that automatically perform many life sciences experiments per day and can be operated, including in collaboration, from afar.

Sources: en.wikipedia.org

Further detail

The Coomassie Blue G250 dye used to bind to the proteins in the original Bradford method readily binds to arginine and lysine groups of proteins. This is a disadvantage because the preference of the dye to bind to these amino acids can result in a varied response of the assay between different proteins. Changes to the original method, such as increasing the pH by adding NaOH or adding more dye have been made to correct this variation. Although these modifications result in a less sensitive assay, a modified method becomes sensitive to detergents that can interfere with sample.

In recent years, the clinical understanding of the FDA's "black box" warning has evolved to focus on the balance between medication risks and the risks of untreated depression. While the 2004 and 2006 warnings regarding increased suicidal ideation in children and young adults (under 25) remain, long-term data published through 2024 suggests that these warnings may have led to an unintended decline in depression treatment, which some studies correlate with an increase in suicide deaths among adolescents. Statistical meta-analyses updated in 2022 confirm that while the risk of suicidal thoughts in youth on antidepressants like fluoxetine is approximately twice that of a placebo (4% vs 2%), there remains no statistically significant increase in completed suicides across dozens of pediatric trials. Furthermore, recent data continues to show a protective effect in older populations; for adults aged 65 and older, antidepressant use is associated with a statistically significant decrease in suicidality. Regarding specific treatments, research published between 2021 and 2023 reinforces that fluoxetine is most effective and carries the lowest risk of adverse behavioral events when paired with psychotherapy. A 2022 meta-analysis found that combination therapy (medication plus CBT) resulted in a lower incidence of suicidal events compared to fluoxetine alone.

==== Moving ==== Employer-paid moving expense benefits were temporarily considered taxable income to the employee, but they are now permanently taxable income. Moving expense benefits for employees who are active-duty members of the U.S. Armed Forces or members of the U.S. Intelligence Community continue to be tax-free to the employee.

==== Training with copyrighted content ==== Generative AI systems such as ChatGPT and Midjourney are trained on large, publicly available datasets that include copyrighted works. AI developers have argued that such training is protected under fair use, while copyright holders have argued that it infringes their rights. Proponents of fair use training have argued that it is a transformative use and does not involve making copies of copyrighted works available to the public. Critics have argued that image generators such as Midjourney can create nearly-identical copies of some copyrighted images, and that generative AI programs compete with the content they are trained on. As of 2024, several lawsuits related to the use of copyrighted material in training are ongoing. Getty Images has sued Stability AI over the use of its images to train Stable Diffusion. Both the Authors Guild and The New York Times have sued Microsoft and OpenAI over the use of their works to train ChatGPT.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

How should the dry powder be stored?

Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.

Network